JP7833399B2 - 眼科用医薬組成物 - Google Patents

眼科用医薬組成物

Info

Publication number
JP7833399B2
JP7833399B2 JP2022533510A JP2022533510A JP7833399B2 JP 7833399 B2 JP7833399 B2 JP 7833399B2 JP 2022533510 A JP2022533510 A JP 2022533510A JP 2022533510 A JP2022533510 A JP 2022533510A JP 7833399 B2 JP7833399 B2 JP 7833399B2
Authority
JP
Japan
Prior art keywords
months
pharmaceutical composition
compound
composition according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505255A5 (https=
JP2023505255A (ja
Inventor
コトレカ，ウダヤ
パドケ，ディーパク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2023505255A publication Critical patent/JP2023505255A/ja
Publication of JP2023505255A5 publication Critical patent/JP2023505255A5/ja
Priority to JP2025117830A priority Critical patent/JP2025160247A/ja
Application granted granted Critical
Publication of JP7833399B2 publication Critical patent/JP7833399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2022533510A 2019-12-05 2020-12-04 眼科用医薬組成物 Active JP7833399B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117830A JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944074P 2019-12-05 2019-12-05
US62/944,074 2019-12-05
US202063077196P 2020-09-11 2020-09-11
US63/077,196 2020-09-11
PCT/US2020/063218 WO2021113580A1 (en) 2019-12-05 2020-12-04 Ophthalmic pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117830A Division JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Publications (3)

Publication Number Publication Date
JP2023505255A JP2023505255A (ja) 2023-02-08
JP2023505255A5 JP2023505255A5 (https=) 2023-12-05
JP7833399B2 true JP7833399B2 (ja) 2026-03-19

Family

ID=74104179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533510A Active JP7833399B2 (ja) 2019-12-05 2020-12-04 眼科用医薬組成物
JP2025117830A Withdrawn JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117830A Withdrawn JP2025160247A (ja) 2019-12-05 2025-07-14 眼科用医薬組成物

Country Status (14)

Country Link
US (1) US20230026577A1 (https=)
EP (1) EP4069195A1 (https=)
JP (2) JP7833399B2 (https=)
KR (1) KR20220128619A (https=)
CN (1) CN115397392A (https=)
AU (1) AU2020398224B2 (https=)
BR (1) BR112022010871A2 (https=)
CA (1) CA3160484A1 (https=)
CL (1) CL2022001463A1 (https=)
CO (1) CO2022009260A2 (https=)
IL (1) IL293541A (https=)
MX (1) MX2022006776A (https=)
TW (1) TWI845795B (https=)
WO (1) WO2021113580A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300628A (en) * 2020-09-10 2023-04-01 Vanda Pharmaceuticals Inc Methods for the treatment of cyclic diseases or conditions-PDE IV
HU231668B1 (hu) * 2021-12-28 2025-06-28 Semmelweis Egyetem 60% Szemcsepp készítmény
US20250073125A1 (en) * 2023-09-06 2025-03-06 Opus Life Sciences, Llc High ph formulations and kits
WO2025179141A1 (en) 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease
KR20260048121A (ko) * 2024-10-02 2026-04-09 주식회사 대웅테라퓨틱스 개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022131A1 (fr) 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
CN101537172A (zh) 2008-08-14 2009-09-23 温州医学院 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
CN101690712B (zh) 2009-08-25 2011-06-15 武汉武药科技有限公司 一种西他沙星滴眼剂及其制备方法
JP2013508383A (ja) 2009-10-20 2013-03-07 アラーガン インコーポレイテッド 瞳孔拡張を調節するための、フェントラミンを含む組成物及び方法
CN102988280A (zh) 2012-10-08 2013-03-27 李正梅 一种加雷沙星滴眼剂
JP2015038099A (ja) 2010-06-29 2015-02-26 ラボラトワール テアＬａｂｏｒａｔｏｉｒｅｓ Ｔｈｅａ 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
US20180236077A1 (en) 2017-02-21 2018-08-23 Avedro, Inc. Formulations for eye treatments
WO2019040919A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California OCULAR PHARMACEUTICAL COMPOSITIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109481392B (zh) * 2015-09-02 2021-12-24 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017083799A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022131A1 (fr) 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
CN101537172A (zh) 2008-08-14 2009-09-23 温州医学院 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
CN101690712B (zh) 2009-08-25 2011-06-15 武汉武药科技有限公司 一种西他沙星滴眼剂及其制备方法
JP2013508383A (ja) 2009-10-20 2013-03-07 アラーガン インコーポレイテッド 瞳孔拡張を調節するための、フェントラミンを含む組成物及び方法
JP2015038099A (ja) 2010-06-29 2015-02-26 ラボラトワール テアＬａｂｏｒａｔｏｉｒｅｓ Ｔｈｅａ 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム
CN102988280A (zh) 2012-10-08 2013-03-27 李正梅 一种加雷沙星滴眼剂
WO2017112951A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
US20180236077A1 (en) 2017-02-21 2018-08-23 Avedro, Inc. Formulations for eye treatments
WO2019040919A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California OCULAR PHARMACEUTICAL COMPOSITIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lee, Sujin, et al，Journal of Medicinal Chemistry，2017年，vol. 60, no. 3，1210 - 1218

Also Published As

Publication number Publication date
KR20220128619A (ko) 2022-09-21
TWI845795B (zh) 2024-06-21
AU2020398224A1 (en) 2022-06-30
AU2020398224B2 (en) 2026-02-19
JP2025160247A (ja) 2025-10-22
WO2021113580A1 (en) 2021-06-10
CA3160484A1 (en) 2021-06-10
CN115397392A (zh) 2022-11-25
CO2022009260A2 (es) 2022-09-20
JP2023505255A (ja) 2023-02-08
TW202128178A (zh) 2021-08-01
BR112022010871A2 (pt) 2022-08-23
EP4069195A1 (en) 2022-10-12
MX2022006776A (es) 2022-09-19
IL293541A (en) 2022-08-01
US20230026577A1 (en) 2023-01-26
CL2022001463A1 (es) 2023-02-10

Similar Documents

Publication Publication Date Title
JP7833399B2 (ja) 眼科用医薬組成物
US20100120908A1 (en) Eye drop preparation comprising latanoprost
US20130065888A1 (en) Ophthalmic formulations and processes for their preparation
US20110065790A1 (en) Latanoprost-containing aqueous pharmaceutical composition
US9561280B2 (en) Aqueous liquid bromfenac composition having preservative efficacy
JP4188084B2 (ja) トラマドールとジクロフェナクの塩の懸濁液を含有する非経口投与可能な剤形
JP2010204597A (ja) ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法
RU2832581C1 (ru) Офтальмологические фармацевтические композиции
JP2016522257A (ja) 安定なブロムフェナク溶液
US6849655B2 (en) Aqueous liquid formulations
US20220265674A1 (en) Parenteral compositions comprising methylene blue
US20120135947A1 (en) Oil-in-water emulsion composition containing difluprednate and tobramycin
US6589999B2 (en) Antibacterial aqueous ophthalmic formulations containing ofloxacin and use of chitosan for solubilizing ofloxacin suspended in an aqueous media
US20170000889A1 (en) Stable bromfenac ophthalmic solution
BR122024022133A2 (pt) Composições farmacêuticas oftalmológicas e uso das mesmas
CN115444849B (zh) 具有改善的防腐效力或光稳定性的眼科药物组合物
EP4595959A1 (en) Sterilized heterocyclidene-acetamide-derivative-containing suspension
JP7053966B2 (ja) 樹脂製容器に充填された銀塩含有眼科用水性組成物
US11097023B1 (en) Pre-filled syringe containing sugammadex
EP4595960A1 (en) Combination preparation containing heterocyclidene acetamide derivative
JP2012532130A (ja) プロピオン酸誘導体を防腐剤として含有する製薬点眼液組成物
JP2011011984A (ja) 仮性近視治療薬
JP2020512997A (ja) 局所用ドキシサイクリン組成物
JPH0676319B2 (ja) トコフェロール類含有液剤
US20200147222A1 (en) Antiseptic agent comprising meglumine or salt thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260309

R150 Certificate of patent or registration of utility model

Ref document number: 7833399

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150